episode-header-image

Aug 2021

18m 34s

Coronapod: COVID boosters amidst global ...

SPRINGER NATURE LIMITED

About this episode

Several wealthy nations have announced plans to give third vaccine doses in a bid to help increase the protection of their most vulnerable citizens - but the science is not clear on whether this strategy will be effective or indeed necessary. Meanwhile with limited vaccine supplies - billions around the world still have no access to vaccines at all. In this episode of Coronapod we discuss the science of boosters, the stark reality of vaccine disparity and what this means for the future of the pandemic.

News: COVID boosters for wealthy nations spark outrage

News feature: COVID vaccine boosters: the most important questions

Coronapod: the inequality at the heart of the pandemic

Coronapod: the biomarker that could change COVID vaccines

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.

Up next

Inside the evidence revolution — how decision-making became data driven

In this episode of Nature hits the books, we speak with Nature's Helen Pearson whose book Beyond Belief: How Evidence Shows What Really Works looks at the history of using evidence, rather than opinion, in decision making.The book traces the course of the movement in various disc ... Show More

Meet Ace, the table-tennis robot that can beat elite players

In this episode:00:45 The table-tennis robot that can mix it with the prosResearch Article: Dürr et al.News and Views: Robot can beat elite players at table tennisVideo: This robot can beat you at table tennis14:13 Research HighlightsNature: Venus’s impenetrable haze could be mad ... Show More

Briefing Chat: Penguins pick up PFAS pollution

In this episode:00:30 The penguins measuring environmental PFASScience: Penguins become marine detectives, thanks to pollutant-detecting anklets05:14 Treating autoimmune diseases with CAR-TNature: One woman, three autoimmune diseases: CAR-T therapy vanquishes ultra-rare disease t ... Show More

Recommended Episodes

The Evidence: When will the pandemic end?

Everybody hopes that the new super-charged Omicron variant of coronavirus will be less severe, but even if it is, it’s spreading so fast and infecting so many people, health services around the world could still buckle under the strain.Two years into the pandemic, Claudia Hammond ... Show More

The Race for a Vaccine

<p>Scientists are racing to make a vaccine for the coronavirus, collaborating across borders in what is usually a secretive and competitive field. But their cooperation has been complicated by national leaders trying to buy first claim on any breakthrough. Today, we explore how t ... Show More

Covipod #9 : Le vaccin, moins efficace chez certaines personnes

<p>Aujourd'hui, dans Covipod, nous nous penchons sur le cas des personnes que les deux doses de vaccin ne suffisent pas à protéger contre la Covid-19, et sur les mesures à prendre pour s'assurer qu'elles n'attrapent pas la maladie. Nous ferons ensuite un bref état des lieux autou ... Show More

The State of Vaccinations

<p>The United States has never undertaken a vaccination campaign of the scale and speed of the Covid-19 program. Despite a few glitches, the country appears to be on track to offer shots to all adults who want one by May 1.</p><p>We look at the ups and downs in the American vacci ... Show More

Vaccine hesitancy, the next pandemic hurdle

As the Pfizer-BioNTech vaccine rolls out across the country, and other vaccines await imminent regulatory approval, many public health experts are focusing on the issue of vaccine hesitancy. Canada's Chief Public Health Officer Dr. Theresa Tam has spoken out about the "moveable m ... Show More

How close are we to a vaccine for Covid-19?

Researchers around the world are racing to develop a vaccine against Covid-19, with more than 170 candidate vaccines now in development. Most vaccines take years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine at reco ... Show More